TWI814187B - 使用ACTRII配位體捕捉以治療β-地中海型貧血 - Google Patents
使用ACTRII配位體捕捉以治療β-地中海型貧血 Download PDFInfo
- Publication number
- TWI814187B TWI814187B TW110148304A TW110148304A TWI814187B TW I814187 B TWI814187 B TW I814187B TW 110148304 A TW110148304 A TW 110148304A TW 110148304 A TW110148304 A TW 110148304A TW I814187 B TWI814187 B TW I814187B
- Authority
- TW
- Taiwan
- Prior art keywords
- certain embodiments
- actriib
- individual
- signaling inhibitor
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161136P | 2015-05-13 | 2015-05-13 | |
| US62/161,136 | 2015-05-13 | ||
| US201562173836P | 2015-06-10 | 2015-06-10 | |
| US62/173,836 | 2015-06-10 | ||
| US201562243457P | 2015-10-19 | 2015-10-19 | |
| US62/243,457 | 2015-10-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202231294A TW202231294A (zh) | 2022-08-16 |
| TWI814187B true TWI814187B (zh) | 2023-09-01 |
Family
ID=57248528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110148304A TWI814187B (zh) | 2015-05-13 | 2016-05-12 | 使用ACTRII配位體捕捉以治療β-地中海型貧血 |
| TW105114763A TWI762444B (zh) | 2015-05-13 | 2016-05-12 | 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105114763A TWI762444B (zh) | 2015-05-13 | 2016-05-12 | 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180125928A1 (https=) |
| EP (1) | EP3294320A4 (https=) |
| JP (2) | JP6976859B2 (https=) |
| KR (1) | KR102640198B1 (https=) |
| CN (1) | CN107847562A (https=) |
| AU (2) | AU2016261913B2 (https=) |
| CA (1) | CA2985777A1 (https=) |
| HK (1) | HK1251157A1 (https=) |
| IL (2) | IL284686B2 (https=) |
| JO (1) | JOP20160092B1 (https=) |
| MY (1) | MY189601A (https=) |
| PH (1) | PH12017502079A1 (https=) |
| TN (1) | TN2017000468A1 (https=) |
| TW (2) | TWI814187B (https=) |
| WO (1) | WO2016183280A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649983T3 (es) | 2005-11-23 | 2018-01-16 | Acceleron Pharma, Inc. | Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| CN108350057A (zh) | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| DK3496739T3 (da) | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| MA45811A (fr) | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| PL3638243T3 (pl) * | 2017-06-14 | 2025-02-10 | Celgene Corporation | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7663502B2 (ja) * | 2018-10-31 | 2025-04-16 | セルジーン コーポレイション | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 |
| EP3999059A1 (en) | 2019-07-19 | 2022-05-25 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt) |
| CN112924684B (zh) * | 2019-12-05 | 2022-07-29 | 中国科学院大连化学物理研究所 | 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒 |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US20230181690A1 (en) * | 2020-04-13 | 2023-06-15 | Celgene Corporation | Methods for treating anemia using an actriib ligand trap and fedratinib |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| US20230270821A1 (en) * | 2020-11-06 | 2023-08-31 | Acceleron Pharma Inc. | Formulations comprising actrii polypeptide variants |
| WO2022150590A1 (en) * | 2021-01-08 | 2022-07-14 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| MX2023008515A (es) | 2021-01-20 | 2023-07-27 | Vifor Int Ag | Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd). |
| KR20260028017A (ko) | 2023-06-26 | 2026-03-03 | 비포르 (인터내셔날) 아게 | 유전성 혈색소침착증(hh)의 치료에 사용하기 위한 페로포틴-저해제 |
| WO2025122830A1 (en) * | 2023-12-08 | 2025-06-12 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247A (en) * | 1845-11-01 | Jordan l | ||
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| CN102131822A (zh) * | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| TW201803586A (zh) * | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| KR20140084211A (ko) * | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| MX2014011836A (es) * | 2012-03-30 | 2015-03-09 | Shire Human Genetic Therapies | Administracion subcutanea de iduronato-2-sulfatasa. |
| CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
| CN109554350B (zh) * | 2012-11-27 | 2022-09-23 | 儿童医疗中心有限公司 | 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件 |
-
2016
- 2016-05-12 US US15/573,177 patent/US20180125928A1/en not_active Abandoned
- 2016-05-12 WO PCT/US2016/031999 patent/WO2016183280A1/en not_active Ceased
- 2016-05-12 TW TW110148304A patent/TWI814187B/zh active
- 2016-05-12 IL IL284686A patent/IL284686B2/en unknown
- 2016-05-12 CN CN201680041002.2A patent/CN107847562A/zh active Pending
- 2016-05-12 TW TW105114763A patent/TWI762444B/zh active
- 2016-05-12 MY MYPI2017704290A patent/MY189601A/en unknown
- 2016-05-12 JO JOP/2016/0092A patent/JOP20160092B1/ar active
- 2016-05-12 KR KR1020177035838A patent/KR102640198B1/ko active Active
- 2016-05-12 EP EP16793499.1A patent/EP3294320A4/en active Pending
- 2016-05-12 AU AU2016261913A patent/AU2016261913B2/en active Active
- 2016-05-12 CA CA2985777A patent/CA2985777A1/en active Pending
- 2016-05-12 HK HK18110608.3A patent/HK1251157A1/zh unknown
- 2016-05-12 TN TNP/2017/000468A patent/TN2017000468A1/en unknown
- 2016-05-12 JP JP2017559025A patent/JP6976859B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-08 IL IL255527A patent/IL255527B/en unknown
- 2017-11-16 PH PH12017502079A patent/PH12017502079A1/en unknown
-
2021
- 2021-08-13 JP JP2021131870A patent/JP2021191755A/ja active Pending
- 2021-10-29 AU AU2021258087A patent/AU2021258087B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 期刊 MD Cappellini, et al. "A Phase 2a, Open-Label, DoseFinding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)- Thalassemia: Interim Results" Blood 122(21):3448 2013 全文 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL255527A (en) | 2018-01-31 |
| TW201709927A (zh) | 2017-03-16 |
| CN107847562A (zh) | 2018-03-27 |
| EP3294320A4 (en) | 2018-12-26 |
| AU2021258087A1 (en) | 2021-11-25 |
| IL255527B (en) | 2021-07-29 |
| JP6976859B2 (ja) | 2021-12-08 |
| HK1251157A1 (zh) | 2019-01-25 |
| TN2017000468A1 (en) | 2019-04-12 |
| WO2016183280A1 (en) | 2016-11-17 |
| AU2016261913A1 (en) | 2017-11-30 |
| IL284686B2 (en) | 2023-05-01 |
| NZ737043A (en) | 2025-02-28 |
| JP2021191755A (ja) | 2021-12-16 |
| MY189601A (en) | 2022-02-18 |
| CA2985777A1 (en) | 2016-11-17 |
| AU2021258087B2 (en) | 2023-04-27 |
| TW202231294A (zh) | 2022-08-16 |
| IL284686B (en) | 2023-01-01 |
| KR102640198B1 (ko) | 2024-02-23 |
| TWI762444B (zh) | 2022-05-01 |
| US20180125928A1 (en) | 2018-05-10 |
| AU2016261913B2 (en) | 2021-08-12 |
| PH12017502079A1 (en) | 2018-06-11 |
| EP3294320A1 (en) | 2018-03-21 |
| KR20180006437A (ko) | 2018-01-17 |
| JOP20160092B1 (ar) | 2023-03-28 |
| IL284686A (en) | 2021-08-31 |
| JP2018520094A (ja) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021258087B2 (en) | Treatment of beta-thalassemia using ActRII ligand traps | |
| AU2021212084B2 (en) | Activin-ActRII antagonists and uses for treating anemia | |
| US20230293634A1 (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
| ES3031001T3 (en) | Biomarker for use in treating anemia | |
| CN111050770A (zh) | 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法 | |
| KR20230010641A (ko) | ACTRIIB 리간드 트랩 및 mTOR 억제제를 사용한 빈혈 치료 방법 및 조성물 | |
| KR20230003502A (ko) | Actriib 리간드 트랩 및 페드라티닙을 사용한 빈혈 치료 방법 | |
| HK1248807B (zh) | 激活素-actrii拮抗剂及用於治疗贫血症的用途 |